{"id":"aripiprazole","rwe":[],"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[],"drugInteractions":[],"commonSideEffects":[{"effect":"Headache","drugRate":"27%","severity":"common","organSystem":""},{"effect":"Nausea","drugRate":"15%","severity":"common","organSystem":""},{"effect":"Constipation","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"11%","severity":"common","organSystem":""},{"effect":"Dyspepsia","drugRate":"9%","severity":"common","organSystem":""},{"effect":"Akathisia","drugRate":"8%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"6%","severity":"common","organSystem":""},{"effect":"Dry Mouth","drugRate":"5%","severity":"common","organSystem":""},{"effect":"Musculoskeletal Stiffness","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Pain in Extremity","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Toothache","drugRate":"4%","severity":"common","organSystem":""},{"effect":"Blurred Vision","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Abdominal Discomfort","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Stomach Discomfort","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Pain","drugRate":"3%","severity":"common","organSystem":""},{"effect":"Myalgia","drugRate":"2%","severity":"common","organSystem":""},{"effect":"Muscle Spasms","drugRate":"2%","severity":"common","organSystem":""}],"contraindications":["Agranulocytosis","Alzheimer's disease","At risk for aspiration","Breastfeeding (mother)","Cerebrovascular disease","Chronic heart failure","Conduction disorder of the heart","Diabetes mellitus","Esophageal dysmotility","Hyperglycemia","Hyperlipidemia","Impaired cognition","Leukopenia","Low blood pressure","Metabolic syndrome X","Myocardial infarction","Myocardial ischemia","Neuroleptic malignant syndrome","Neutropenic disorder","Obesity","Orthostatic hypotension","Seizure disorder","Senile dementia","Suicidal thoughts","Tardive dyskinesia"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT00705783","NCT00299702","NCT06590298","NCT01111539","NCT01909466","NCT00905307","NCT01617447","NCT01724372","NCT01085383","NCT01592201","NCT02717130","NCT02213887","NCT01813643","NCT00541554","NCT00704860","NCT00956189","NCT02339844","NCT03854409","NCT02040883","NCT00365339","NCT01509053","NCT01727713","NCT02131415","NCT01416441","NCT00606177","NCT02007928","NCT06054321","NCT01617460","NCT00876343","NCT00080314","NCT00312598","NCT02435095","NCT01185418","NCT01765829","NCT03285503","NCT00873795","NCT02532491","NCT06581302","NCT04903353","NCT00223496","NCT00706589","NCT02526030","NCT02146547","NCT06591091","NCT03892889","NCT03232710","NCT05686772","NCT00097266","NCT00332241","NCT01490086"],"aliases":["Abilify","Abilify Maintena","Aristada"],"patents":[{"type":"Method of Use","number":"8759350","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY","expiryDate":"2027-03-02"},{"type":"Method of Use","number":"9125939","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY","expiryDate":"2026-07-28"},{"type":"Formulation","number":"8945005","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-08-19"},{"type":"Formulation","number":"8956288","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-07-06"},{"type":"Formulation","number":"8547248","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2030-12-18"},{"type":"Formulation","number":"9268909","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2033-10-15"},{"type":"Formulation","number":"8674825","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-04-09"},{"type":"Formulation","number":"8847766","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2030-03-29"},{"type":"Formulation","number":"9444503","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2027-11-19"},{"type":"Method of Use","number":"10525057","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MAINTENA KIT","expiryDate":"2034-03-08"},{"type":"Method of Use","number":"11344547","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MAINTENA KIT","expiryDate":"2033-09-24"},{"type":"Formulation","number":"12016927","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY ASIMTUFII","expiryDate":"2033-04-23"},{"type":"Method of Use","number":"11400087","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MAINTENA KIT","expiryDate":"2033-09-24"},{"type":"Formulation","number":"11638757","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY ASIMTUFII","expiryDate":"2033-04-23"},{"type":"Formulation","number":"11097007","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY ASIMTUFII","expiryDate":"2033-04-23"},{"type":"Formulation","number":"10517951","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY ASIMTUFII","expiryDate":"2033-04-23"},{"type":"Method of Use","number":"10980803","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MAINTENA KIT","expiryDate":"2033-09-24"},{"type":"Method of Use","number":"11154553","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MAINTENA KIT","expiryDate":"2033-09-24"},{"type":"Formulation","number":"9433371","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-09-15"},{"type":"Formulation","number":"9149577","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-12-15"},{"type":"Formulation","number":"7978064","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2026-09-14"},{"type":"Formulation","number":"9119554","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2028-12-16"},{"type":"Formulation","number":"8114021","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2030-06-21"},{"type":"Formulation","number":"11331315","applicant":"XIAMEN LP PHARMACUETICAL CO LTD","territory":"US","tradeName":"OPIPZA","expiryDate":"2040-11-03"},{"type":"Formulation","number":"11229378","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2031-07-11"},{"type":"Formulation","number":"8718193","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-12-05"},{"type":"Formulation","number":"11464423","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2030-09-15"},{"type":"Formulation","number":"8258962","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2030-11-25"},{"type":"Formulation","number":"8961412","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2030-11-17"},{"type":"Formulation","number":"9060708","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-03-05"},{"type":"Formulation","number":"10441194","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-07-26"},{"type":"Formulation","number":"9320455","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2031-12-15"},{"type":"Formulation","number":"9258035","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2029-03-05"},{"type":"Formulation","number":"11476952","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2026-04-28"},{"type":"Formulation","number":"11701352","applicant":"XIAMEN LP PHARMACUETICAL CO LTD","territory":"US","tradeName":"OPIPZA","expiryDate":"2041-12-15"},{"type":"Formulation","number":"11648347","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MAINTENA KIT","expiryDate":"2034-04-06"},{"type":"Formulation","number":"10517507","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2032-06-13"},{"type":"Formulation","number":"8545402","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2030-04-27"},{"type":"Formulation","number":"9694008","applicant":"CMG PHARMACEUTICAL CO LTD","territory":"US","tradeName":"MEZOFY","expiryDate":"2033-08-07"},{"type":"Formulation","number":"9941931","applicant":"OTSUKA PHARMACEUTICAL CO LTD","territory":"US","tradeName":"ABILIFY MYCITE KIT","expiryDate":"2030-11-04"}],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.6997/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$252","description":"ARIPIPRAZOLE 1 MG/ML SOLUTION","retrievedDate":"2026-04-07"}],"allNames":"abilify","offLabel":[],"timeline":[],"aiSummary":"Aripiprazole (Abilify) is a third-generation antipsychotic with a unique partial agonist mechanism, developed by Otsuka and approved in 2002. Less metabolic disruption than other atypicals. Available generically.","brandName":"Abilify","companyId":"unknown","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 1E, 5-hydroxytryptamine receptor 5A, 5-hydroxytryptamine receptor 6","novelty":"","modality":"Small molecule","drugClass":"Third-generation antipsychotic (D2 partial agonist)","explanation":"Aripiprazole has a unique mechanism as a dopamine partial agonist — it stabilizes dopamine transmission by acting as an agonist where dopamine is low (negative symptoms) and antagonist where dopamine is high (positive symptoms). This \\","oneSentence":"Third-generation antipsychotic that acts as a partial agonist at D2 and 5-HT1A receptors, stabilizing dopamine activity rather than simply blocking it.","technicalDetail":""},"commercial":{"revenueYear":2024,"annualRevenue":3000,"revenueSource":"Verified: Otsuka AR","revenueCurrency":"USD","revenueConfidence":"verified"},"references":[],"biosimilars":[],"companyName":"Generic (originally Otsuka/BMS)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"aripiprazole","indications":{"approved":[{"name":"Agitation associated with Bipolar Mania","diseaseId":"agitation-associated-with-bipolar-mania","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Agitation associated with Schizophrenia","diseaseId":"agitation-associated-with-schizophrenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bipolar affective disorder, current episode manic","diseaseId":"bipolar-affective-disorder-current-episode-manic","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bipolar disorder in remission","diseaseId":"bipolar-disorder-in-remission","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Depression Treatment Adjunct","diseaseId":"depression-treatment-adjunct","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infantile autism","diseaseId":"infantile-autism","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Mixed bipolar I disorder","diseaseId":"mixed-bipolar-i-disorder","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Schizophrenia","diseaseId":"schizophrenia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00705783","phase":"Phase 3","title":"A 52-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of an Intramuscular Depot Formulation of Aripiprazole as Maintenance Treat","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":843,"indication":"Schizophrenia","completionDate":"2011-02"},{"nctId":"NCT00299702","phase":"Phase 4","title":"A 2-year, Prospective, Blinded-rater, Open-label, Active-controlled, Multicenter, Randomized Study of Long-term Efficacy and Effectiveness Comparing Risperdal® Consta® and Abilify® (Aripiprazole) in A","status":"COMPLETED","sponsor":"Johnson & Johnson Pharmaceutical Research & Development, L.L.C.","isPivotal":false,"enrollment":355,"indication":"Schizophrenia, Psychotic Disorders","completionDate":"2009-01"},{"nctId":"NCT06590298","phase":"Phase 4","title":"Evaluating the Effects of Adjunctive Aripiprazole on Weight and Metabolic Outcomes in Females Receiving Atypical Antipsychotics: A Randomized Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"Universiti Putra Malaysia","isPivotal":false,"enrollment":600,"indication":"Psychosis, Metabolic Syndrome","completionDate":"2025-04-10"},{"nctId":"NCT01111539","phase":"Phase 3","title":"A Multicenter, Randomized, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Patients With Major Depressive Disorder","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":211,"indication":"Major Depressive Disorder (MDD)","completionDate":"2011-09-20"},{"nctId":"NCT01909466","phase":"Phase 1","title":"An Open-label, Multiple Dose, Safety and Tolerability Study of Aripiprazole IM Depot Administered in the Deltoid Muscle in Adult Subjects With Schizophrenia","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":false,"enrollment":141,"indication":"Schizophrenia, Mental Disorder","completionDate":"2014-04"},{"nctId":"NCT00905307","phase":"Phase 2","title":"A Phase 2, 6-Week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Oral OPC-34712 Once Daily and Aripiprazole Once Daily for Treat","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":false,"enrollment":459,"indication":"Schizophrenia","completionDate":"2010-11"},{"nctId":"NCT01617447","phase":"Phase 3","title":"A Short-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":92,"indication":"Autistic Disorder","completionDate":"2015-06"},{"nctId":"NCT01724372","phase":"NA","title":"The Role of Antidepressants or Antipsychotics in Preventing Psychosis","status":"WITHDRAWN","sponsor":"St. Luke's-Roosevelt Hospital Center","isPivotal":false,"enrollment":0,"indication":"Psychotic Disorder","completionDate":"2014-05"},{"nctId":"NCT01085383","phase":"Phase 4","title":"Aripiprazole Treatment for Antipsychotic Induced Hyperprolactinaemia in Patients With Severe Mental Illness and Learning Disabilities","status":"COMPLETED","sponsor":"University of Oxford","isPivotal":false,"enrollment":15,"indication":"Hyperprolactinemia","completionDate":"2014-12"},{"nctId":"NCT01592201","phase":"Phase 4","title":"An Open-label, Prospective, Randomized and Comparative Study of Patient Satisfaction Between Continued Administration of Previous Antipsychotics Versus Switched Administration to Paliperidone ER in No","status":"TERMINATED","sponsor":"Janssen Korea, Ltd., Korea","isPivotal":false,"enrollment":13,"indication":"Schizophrenia","completionDate":"2013-06"},{"nctId":"NCT02717130","phase":"NA","title":"Aripiprazole, Abilify Maintena Collaborative Clinical Protocol","status":"TERMINATED","sponsor":"Florida Atlantic University","isPivotal":false,"enrollment":9,"indication":"Schizophrenia","completionDate":"2017-05-25"},{"nctId":"NCT02213887","phase":"Phase 4","title":"A Pilot Study to Determine if Pantoprazole Modifies Steady-State Plasma Concentrations of Orally Administered Psychotropic Medications","status":"WITHDRAWN","sponsor":"University of British Columbia","isPivotal":false,"enrollment":0,"indication":"Psychotic Disorders, Gastroesophageal Reflux","completionDate":"2020-11-02"},{"nctId":"NCT01813643","phase":"Phase 4","title":"A Multiple-Center, Randomized, Double-Blind Study of Comparison of Risperidone and Aripiprazole for Treatment","status":"TERMINATED","sponsor":"Wei Hao","isPivotal":false,"enrollment":50,"indication":"Methamphetamine Dependence","completionDate":"2014-08"},{"nctId":"NCT00541554","phase":"Phase 4","title":"Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label T","status":"UNKNOWN","sponsor":"Genovate Biotechnology Co., Ltd.,","isPivotal":false,"enrollment":0,"indication":"Hyperprolactinemia, Weight Gain","completionDate":"2009-02"},{"nctId":"NCT00704860","phase":"Phase 4","title":"Treatment-Resistant Depression, Hippocampus Atrophy and Serotonin Genetic Polymorphism","status":"COMPLETED","sponsor":"University of Ottawa","isPivotal":false,"enrollment":27,"indication":"Major Depression","completionDate":"2010-12"},{"nctId":"NCT00956189","phase":"NA","title":"Easy Identification, Treatment Response Prediction, and Molecular Mechanism Exploration of Antipsychotic-related Metabolic Syndrome","status":"COMPLETED","sponsor":"National Taiwan University Hospital","isPivotal":false,"enrollment":132,"indication":"Metabolic Syndrome X","completionDate":"2012-10"},{"nctId":"NCT02339844","phase":"Phase 4","title":"Pan European Collaboration on Antipsychotic Naïve Schizophrenia II","status":"COMPLETED","sponsor":"University of Copenhagen","isPivotal":false,"enrollment":130,"indication":"Schizophrenia","completionDate":"2021-01"},{"nctId":"NCT03854409","phase":"Phase 1","title":"An Open-label, Single- and Multiple-dose, Pharmacokinetic, Safety, and Tolerability Trial of Aripiprazole Long-acting Injectable Administered in the Deltoid or Gluteal Muscle in Adult Subjects With Sc","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":false,"enrollment":72,"indication":"Schizophrenia, Bipolar I Disorder","completionDate":"2020-02-20"},{"nctId":"NCT02040883","phase":"Phase 4","title":"Phase 4 Study of Efficacy and Safety of Tandospirone Combined With Atypical Antipsychotic Drugs to Improve Cognitive Function in Schizophrenia","status":"UNKNOWN","sponsor":"Qingyun Yin","isPivotal":false,"enrollment":100,"indication":"Schizophrenia","completionDate":"2014-12"},{"nctId":"NCT00365339","phase":"Phase 1","title":"Randomized, Open-Label, Multiple-Dose Study to Evaluate the Effect of Famotidine on the Pharmacokinetics of Atazanavir/Ritonavir/Tenofovir in Healthy Subjects","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","isPivotal":false,"enrollment":40,"indication":"HIV Infections","completionDate":"2006-06"},{"nctId":"NCT01509053","phase":"Phase 3","title":"Open-label Study to Assess Hospitalization Rates in Adult Schizophrenic Patients Treated With Oral Antipsychotics for 6 Months and IM Depot Aripiprazole for 6 Months, Respectively, in a Naturalistic C","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":30,"indication":"Schizophrenia","completionDate":"2012-10"},{"nctId":"NCT01727713","phase":"Phase 3","title":"An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-daily Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":110,"indication":"Tourette's Disorder, Tic Disorder","completionDate":"2014-09"},{"nctId":"NCT02131415","phase":"N/A","title":"Canadian Non-Interventional Prospective Cohort Study on the Real - Life Assessment of Abilify Maintena ™ in Schizophrenia","status":"TERMINATED","sponsor":"Lundbeck Canada Inc.","isPivotal":false,"enrollment":200,"indication":"Schizophrenia","completionDate":"2017-02-15"},{"nctId":"NCT01416441","phase":"Phase 3","title":"An Open-Label, Multicenter Study Evaluating the Safety and Tolerability of Once-weekly Oral Aripiprazole in Children and Adolescents With Tourette's Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":170,"indication":"Tourette's Disorder","completionDate":"2014-03-13"},{"nctId":"NCT00606177","phase":"Phase 3","title":"A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixe","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":99,"indication":"Bipolar I Disorder","completionDate":"2010-11"},{"nctId":"NCT02007928","phase":"NA","title":"Assessment of Incidence of Adverse Events in a Naive Pediatric Population Treated With an (Typical and Atypical) Antipsychotic Drug Over 12 Months Follow-up","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nice","isPivotal":false,"enrollment":200,"indication":"Dissociative Disorders, Schizophrenia","completionDate":"2017-07"},{"nctId":"NCT06054321","phase":"NA","title":"A Randomized Clinical Trial of Response to Psychopharmacotherapy According to Multimodal Serum Biomarkers in Depressive Patients","status":"RECRUITING","sponsor":"Chonnam National University Hospital","isPivotal":false,"enrollment":400,"indication":"Major Depressive Disorder","completionDate":"2030-12-31"},{"nctId":"NCT01617460","phase":"Phase 3","title":"A Long-term Administration Study of Aripiprazole in Children and Adolescents (Age: 6 to 17 Years) With Autistic Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":86,"indication":"Autistic Disorder","completionDate":"2016-10"},{"nctId":"NCT00876343","phase":"Phase 3","title":"Placebo-Controlled, Double-Blind, Parallel Group-Comparison Study of Aripiprazole as an Adjunctive Therapy in Patients With Major Depressive Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":586,"indication":"Major Depressive Disorder","completionDate":"2012-07"},{"nctId":"NCT00080314","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Aripiprazole in the Treatment of Patients With Bipolar I Disorder With a Major Depressive Episode","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":400,"indication":"Bipolar Disorder","completionDate":"2006-10"},{"nctId":"NCT00312598","phase":"N/A","title":"Investigation of Body Mass Index, Body Composition, Resting Energy Expenditure, Respiratory Quotient and Metabolic Changes Following a Switch From Olanzapine, Quetiapine or Risperidone to Aripiprazole","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","isPivotal":false,"enrollment":30,"indication":"Schizophrenia, Schizoaffective Disorder","completionDate":"2010-04"},{"nctId":"NCT02435095","phase":"Phase 4","title":"Are Antipsychotics Neurotoxic or Neuroprotective? A Long-term Comparison of Two Treatment Strategies","status":"TERMINATED","sponsor":"RWTH Aachen University","isPivotal":false,"enrollment":174,"indication":"Schizophrenia","completionDate":"2020-08"},{"nctId":"NCT01185418","phase":"N/A","title":"Evaluation of Negative Symptoms and Cognitive Function After Administration of Antipsychotics in Healthy Volunteer: a Double-blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, Amisulpri","status":"COMPLETED","sponsor":"Chonbuk National University Hospital","isPivotal":false,"enrollment":80,"indication":"Normal Volunteers","completionDate":"2009-07"},{"nctId":"NCT01765829","phase":"Phase 3","title":"Randomized Multicentric Open-label Phase III Clinical Trial to Evaluate the Efficacy of Continual Treatment Versus Discontinuation Based in the Presence of Prodromes in a First Episode of Non-affectiv","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","isPivotal":true,"enrollment":104,"indication":"Psychosis Nos/Other","completionDate":"2015-11"},{"nctId":"NCT03285503","phase":"Phase 1","title":"A Single-center, Uncontrolled, Open-label Clinical Trial Evaluating the Pharmacokinetic Characteristics and Safety of Aripiprazole IM Depot in Chinese Patients With Schizophrenia After Multi-dose Admi","status":"COMPLETED","sponsor":"Otsuka Beijing Research Institute","isPivotal":false,"enrollment":12,"indication":"Schizophrenia","completionDate":"2019-10-14"},{"nctId":"NCT00873795","phase":"NA","title":"Efficacy and Safety of Aripiprazole 2.5mg Combine Sertraline 50mg in Major Depression","status":"COMPLETED","sponsor":"Chimei Medical Center","isPivotal":false,"enrollment":41,"indication":"Major Depressive Disorder","completionDate":"2009-03"},{"nctId":"NCT02532491","phase":"Phase 4","title":"Open Flexible-dose Randomized Study of the Effectiveness of Second Generation Antipsychotics in First Episode Psychosis Patients: A 1-year Follow-up","status":"UNKNOWN","sponsor":"Fundación Marques de Valdecilla","isPivotal":false,"enrollment":200,"indication":"Schizophrenia, Psychotic Disorders","completionDate":"2020-12"},{"nctId":"NCT06581302","phase":"NA","title":"Accelerated 100Hz Magnetic Seizure Therapy for Psychotic Disorders","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","isPivotal":false,"enrollment":50,"indication":"Psychotic Disorders","completionDate":"2025-12-30"},{"nctId":"NCT04903353","phase":"Phase 4","title":"Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","isPivotal":false,"enrollment":31,"indication":"Weight Gain, Autism Spectrum Disorder","completionDate":"2025-12-01"},{"nctId":"NCT00223496","phase":"Phase 4","title":"12- Week Open Label Treatment of Refractory Bipolar Depression (BD) With Combination of Depakote ER (DEP) and Aripiprazole (AZP)","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","isPivotal":false,"enrollment":32,"indication":"Bipolar Disorder","completionDate":"2009-09"},{"nctId":"NCT00706589","phase":"Phase 3","title":"A Randomized, Double-blind, Dose-adjustment, Placebo-controlled Study to Evaluate the Efficacy and Safety of Aripiprazole in Children and Adolescents With Chronic Tic Disorders or Tourette's Disorder","status":"COMPLETED","sponsor":"Korea Otsuka Pharmaceutical Co., Ltd.","isPivotal":true,"enrollment":61,"indication":"Chronic Motor or Vocal Tic Disorder, Tourette's Disorder","completionDate":"2010-04"},{"nctId":"NCT02526030","phase":"Phase 4","title":"Phase IV Study of Effectiveness of Aripiprazole, Quetiapine, and Ziprasidone in the Treatment of First Episode of Non-affective Psychosis Individuals Included in the First Episode Psychosis Clinical P","status":"COMPLETED","sponsor":"Fundación Marques de Valdecilla","isPivotal":false,"enrollment":203,"indication":"Schizophrenia, Psychotic Disorders","completionDate":"2015-06"},{"nctId":"NCT02146547","phase":"Phase 4","title":"European Long-acting Antipsychotics in Schizophrenia Trial","status":"COMPLETED","sponsor":"UMC Utrecht","isPivotal":false,"enrollment":536,"indication":"Schizophrenia","completionDate":"2020-08-26"},{"nctId":"NCT06591091","phase":"Phase 2","title":"Clemastine for Improving White Matter and Boosting Antidepressant Response in Late-life Depression","status":"NOT_YET_RECRUITING","sponsor":"University of Illinois at Chicago","isPivotal":false,"enrollment":80,"indication":"Depression","completionDate":"2026-03"},{"nctId":"NCT03892889","phase":"Phase 3","title":"A Phase IIIb Multi-Center, Open-Label, Mirror-Image, Trial in Adult Subjects With Schizophrenia Treated Prospectively for 6-months With Abilify MyCite®","status":"TERMINATED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":277,"indication":"Schizophrenia","completionDate":"2020-09-29"},{"nctId":"NCT03232710","phase":"NA","title":"A Single-dose, Two-treatment, Two-sequence, Two-period, Two Way Crossover Bioequivalence Study of Bosiqing Aripiprazole Orally Disintegrating Tablets and ABILIFY Under Fasting/Fed Condition","status":"UNKNOWN","sponsor":"Chengdu Kanghong Pharmaceutical Group Co., Ltd.","isPivotal":false,"enrollment":66,"indication":"Bioequivalence","completionDate":"2018-06-30"},{"nctId":"NCT05686772","phase":"N/A","title":"A Better Understanding of the Association Between Problem Gambling and Psychotic Disorders in Young Adults: a New Path Towards Recovery","status":"COMPLETED","sponsor":"Laval University","isPivotal":false,"enrollment":520,"indication":"Gambling Disorder, Psychotic Disorders","completionDate":"2023-05-01"},{"nctId":"NCT00097266","phase":"Phase 3","title":"A Multicenter, Randomized, Double-Blind, Placebo Controlled Study of Aripiprazole Monotherapy in the Treatment of Acutely Manic Patients With Bipolar I Disorder","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":615,"indication":"Bipolar Disorder","completionDate":"2007-01"},{"nctId":"NCT00332241","phase":"Phase 3","title":"A Multicenter Double-Blind, Randomized, Placebo-Controlled, Flexible-Dosed, Parallel-Group Study of Aripiprazole Flexibly Dosed in the Treatment of Children and Adolescents With Autistic Disorder (AD)","status":"COMPLETED","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","isPivotal":true,"enrollment":98,"indication":"Autistic Disorder","completionDate":"2008-04"},{"nctId":"NCT01490086","phase":"Phase 2","title":"REFRESH : Randomized Double-blind, Placebo-controlled, Multicenter Trial to Assess the Safety and Efficacy of RP5063 in Subjects With an Acute Exacerbation of Schizophrenia or Schizoaffective Disorder","status":"COMPLETED","sponsor":"Reviva Pharmaceuticals","isPivotal":false,"enrollment":234,"indication":"Acute Schizophrenia, Schizoaffective Disorder","completionDate":"2013-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral, Intramuscular (long-acting injectable)","frequency":"Once daily","formulation":"Tablet, Orally disintegrating tablet, Oral solution, Long-acting injectable"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"therapeuticAreas":["Neuroscience"],"_revenueScrapedAt":"2026-04-08 13:58:22.723226+00","biosimilarFilings":[],"firstApprovalDate":"2002-11-15","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":"EMEA/H/C/004008"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aripiprazole Sandoz","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"patentsNormalised":[{"patent_number":"11476952","territory":"US","patent_type":"Formulation","expiry_date":"2026-04-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9125939","territory":"US","patent_type":"Method of Use","expiry_date":"2026-07-28T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"7978064","territory":"US","patent_type":"Formulation","expiry_date":"2026-09-14T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8759350","territory":"US","patent_type":"Method of Use","expiry_date":"2027-03-02T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9444503","territory":"US","patent_type":"Formulation","expiry_date":"2027-11-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9119554","territory":"US","patent_type":"Formulation","expiry_date":"2028-12-16T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9060708","territory":"US","patent_type":"Formulation","expiry_date":"2029-03-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9258035","territory":"US","patent_type":"Formulation","expiry_date":"2029-03-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8674825","territory":"US","patent_type":"Formulation","expiry_date":"2029-04-09T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8956288","territory":"US","patent_type":"Formulation","expiry_date":"2029-07-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10441194","territory":"US","patent_type":"Formulation","expiry_date":"2029-07-26T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8945005","territory":"US","patent_type":"Formulation","expiry_date":"2029-08-19T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9433371","territory":"US","patent_type":"Formulation","expiry_date":"2029-09-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8718193","territory":"US","patent_type":"Formulation","expiry_date":"2029-12-05T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9149577","territory":"US","patent_type":"Formulation","expiry_date":"2029-12-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8847766","territory":"US","patent_type":"Formulation","expiry_date":"2030-03-29T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8545402","territory":"US","patent_type":"Formulation","expiry_date":"2030-04-27T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8114021","territory":"US","patent_type":"Formulation","expiry_date":"2030-06-21T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11464423","territory":"US","patent_type":"Formulation","expiry_date":"2030-09-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9941931","territory":"US","patent_type":"Formulation","expiry_date":"2030-11-04T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8961412","territory":"US","patent_type":"Formulation","expiry_date":"2030-11-17T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8258962","territory":"US","patent_type":"Formulation","expiry_date":"2030-11-25T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"8547248","territory":"US","patent_type":"Formulation","expiry_date":"2030-12-18T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11229378","territory":"US","patent_type":"Formulation","expiry_date":"2031-07-11T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9320455","territory":"US","patent_type":"Formulation","expiry_date":"2031-12-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10517507","territory":"US","patent_type":"Formulation","expiry_date":"2032-06-13T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"12016927","territory":"US","patent_type":"Formulation","expiry_date":"2033-04-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10517951","territory":"US","patent_type":"Formulation","expiry_date":"2033-04-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11097007","territory":"US","patent_type":"Formulation","expiry_date":"2033-04-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11638757","territory":"US","patent_type":"Formulation","expiry_date":"2033-04-23T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9694008","territory":"US","patent_type":"Formulation","expiry_date":"2033-08-07T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11400087","territory":"US","patent_type":"Method of Use","expiry_date":"2033-09-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11344547","territory":"US","patent_type":"Method of Use","expiry_date":"2033-09-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11154553","territory":"US","patent_type":"Method of Use","expiry_date":"2033-09-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10980803","territory":"US","patent_type":"Method of Use","expiry_date":"2033-09-24T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"9268909","territory":"US","patent_type":"Formulation","expiry_date":"2033-10-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"10525057","territory":"US","patent_type":"Method of Use","expiry_date":"2034-03-08T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11648347","territory":"US","patent_type":"Formulation","expiry_date":"2034-04-06T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11331315","territory":"US","patent_type":"Formulation","expiry_date":"2040-11-03T00:00:00.000Z","status":"active","paragraph_iv_filed":false},{"patent_number":"11701352","territory":"US","patent_type":"Formulation","expiry_date":"2041-12-15T00:00:00.000Z","status":"active","paragraph_iv_filed":false}],"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}